Cellular reprogramming: A new technology frontier in pharmaceutical research

Amy Brock; Hui Tong Goh; Binxia Yang; Yu Lu; Hu Li; Yuin Han Loh

doi:10.1007/s11095-011-0618-z

Cellular reprogramming: A new technology frontier in pharmaceutical research

Amy Brock, Hui Tong Goh, Binxia Yang, Yu Lu, Hu Li, Yuin Han Loh

Pharmacology

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

Original language	English (US)
Pages (from-to)	35-52
Number of pages	18
Journal	Pharmaceutical research
Volume	29
Issue number	1
DOIs	https://doi.org/10.1007/s11095-011-0618-z
State	Published - Jan 2012

Keywords

Cellular reprogramming
Drug discovery
IPSC
Pharmaceutical research
Stem cells

ASJC Scopus subject areas

Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Organic Chemistry
Pharmacology (medical)

Access to Document

10.1007/s11095-011-0618-z

Cite this

@article{7b4aa0bae726406d8009a0ea68cf4d2b,

title = "Cellular reprogramming: A new technology frontier in pharmaceutical research",

abstract = "Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.",

keywords = "Cellular reprogramming, Drug discovery, IPSC, Pharmaceutical research, Stem cells",

author = "Amy Brock and Goh, {Hui Tong} and Binxia Yang and Yu Lu and Hu Li and Loh, {Yuin Han}",

note = "Funding Information: We are grateful to Dr. Keith Pardee and Dr. Roshan Kumar for their discussion and comments on the manuscript. We thank Drs. James J. Collins, George Q. Daley and Donald E. Ingber for their supports on this work. Y-H.L. is supported by the A*Star Inves-tigatorship award. We are grateful to the Wyss Institute, Harvard Medical School, the Dept. of Biomedical Engineering, Boston University and the Biomedical Research Council, Agency for Science, Technology and Research, Singapore.",

year = "2012",

month = jan,

doi = "10.1007/s11095-011-0618-z",

language = "English (US)",

volume = "29",

pages = "35--52",

journal = "Pharmaceutical research",

issn = "0724-8741",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Cellular reprogramming

T2 - A new technology frontier in pharmaceutical research

AU - Brock, Amy

AU - Goh, Hui Tong

AU - Yang, Binxia

AU - Lu, Yu

AU - Li, Hu

AU - Loh, Yuin Han

N1 - Funding Information: We are grateful to Dr. Keith Pardee and Dr. Roshan Kumar for their discussion and comments on the manuscript. We thank Drs. James J. Collins, George Q. Daley and Donald E. Ingber for their supports on this work. Y-H.L. is supported by the A*Star Inves-tigatorship award. We are grateful to the Wyss Institute, Harvard Medical School, the Dept. of Biomedical Engineering, Boston University and the Biomedical Research Council, Agency for Science, Technology and Research, Singapore.

PY - 2012/1

Y1 - 2012/1

N2 - Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

AB - Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

KW - Cellular reprogramming

KW - Drug discovery

KW - IPSC

KW - Pharmaceutical research

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84860598122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860598122&partnerID=8YFLogxK

U2 - 10.1007/s11095-011-0618-z

DO - 10.1007/s11095-011-0618-z

M3 - Review article

C2 - 22068279

AN - SCOPUS:84860598122

SN - 0724-8741

VL - 29

SP - 35

EP - 52

JO - Pharmaceutical research

JF - Pharmaceutical research

IS - 1

ER -

Cellular reprogramming: A new technology frontier in pharmaceutical research

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this